Nan Lu

Dr. Nan Lu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
JLJiajia Lu
Jiajia Lu
XSXiaojian Shi
Xiaojian Shi
QFQiang Fu
Qiang Fu
YHYaguang Han
Yaguang Han
LZLei Zhu
Lei Zhu
NLNan Lu
Nan Lu
Objective: Osteoporosis is a global health issue characterized by decreased bone mass and microstructural degradation, leading to an increased risk of fractures. This study aims to explore the molecular mechanism by which P2X7 receptors influence osteoclast formation and bone resorption through the PI3K-Akt-GSK3β signaling pathway. Methods: An osteoporosis mouse model was generated through ovariectomy (OVX) in normal C57BL/6 and P2X7f/f; LysM-cre mice. Osteoclasts were isolated for transcriptomic analysis, and differentially expressed genes were selected for functional enrichment analysis. Metabolite analysis was performed using liquid chromatography-tandem mass spectrometry (LC–MS/MS), and multivariate statistical analysis and pattern recognition were used to identify differential lipid metabolism markers and their distribution. Bioinformatics analyses were conducted using the Encyclopedia of Genes and Genomes database and the MetaboAnalyst database to assess potential biomarkers and create a metabolic pathway map. Osteoclast precursor cells were used for in vitro cell experiments, evaluating cell viability and proliferation using the Cell Counting Kit 8 (CCK-8) assay. Osteoclast precursor cells were induced to differentiate into osteoclasts using macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-beta ligand (RANKL), and tartrate-resistant acid phosphatase (TRAP) staining was performed to compare differentiation morphology, size, and quantity between different groups. Western blot analysis was used to assess the expression of differentiation markers, fusion gene markers, and bone resorption ability markers in osteoclasts. Immunofluorescence staining was employed to examine the spatial distribution and quantity of osteoclast cell skeletons, P2X7 protein, and cell nuclei, while pit assay was used to evaluate osteoclast bone resorption ability. Finally, in vivo animal experiments, including micro computed tomography (micro-CT), hematoxylin and eosin (HE) staining, TRAP staining, and immunohistochemistry, were conducted to observe bone tissue morphology, osteoclast differentiation, and the phosphorylation level of the PI3K-Akt-GSK3β signaling pathway. Results: Transcriptomic and metabolomic data collectively reveal that the P2X7 receptor can impact the pathogenesis of osteoporosis through the PI3K-Akt-GSK3β signaling pathway. Subsequent in vitro experiments showed that cells in the Sh-P2X7 + Recilisib group exhibited increased proliferative activity (1.15 versus 0.59), higher absorbance levels (0.68 versus 0.34), and a significant increase in resorption pit area (13.94 versus 3.50). Expression levels of osteoclast differentiation-related proteins MMP-9, CK, and NFATc1 were markedly elevated (MMP-9: 1.72 versus 0.96; CK: 2.54 versus 0.95; NFATc1: 3.05 versus 0.95), along with increased fluorescent intensity of F-actin rings. In contrast, the OE-P2X7 + LY294002 group showed decreased proliferative activity (0.64 versus 1.29), reduced absorbance (0.34 versus 0.82), and a significant decrease in resorption pit area (5.01 versus 14.96), accompanied by weakened expression of MMP-9, CK, and NFATc1 (MMP-9: 1.14 versus 1.79; CK: 1.26 versus 2.75; NFATc1: 1.17 versus 2.90) and decreased F-actin fluorescent intensity. Furthermore, in vivo animal experiments demonstrated that compared with the wild type (WT) + Sham group, mice in the WT + OVX group exhibited significantly increased levels of CTX and NTX in serum (CTX: 587.17 versus 129.33; NTX: 386.00 versus 98.83), a notable decrease in calcium deposition (19.67 versus 53.83), significant reduction in bone density, increased trabecular separation, and lowered bone mineral density (BMD). When compared with the KO + OVX group, mice in the KO + OVX + recilisib group showed a substantial increase in CTX and NTX levels in serum (CTX: 503.50 versus 209.83; NTX: 339.83 versus 127.00), further reduction in calcium deposition (29.67 versus 45.33), as well as decreased bone density, increased trabecular separation, and reduced BMD. Conclusion: P2X7 receptors positively regulate osteoclast formation and bone resorption by activating the PI3K-Akt-GSK3β signaling pathway.

19 January 2018 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
AYAnan Yin
Anan Yin
NLNan Lu
Nan Lu
AEAmandine Etcheverry
Amandine Etcheverry
MAMarc Aubry
Marc Aubry
JIll S Barnholt-SloanJIll S Barnholt-Sloan
JIll S Barnholt-Sloan
YHYalong He
Yalong He
Summary: Aims: We aimed to identify a clinically useful biomarker using DNA methylation‐based information to optimize individual treatment of patients with glioblastoma (GBM).Methods: A six‐CpG panel was identified by incorporating genome‐wide DNA methylation data and clinical information of three distinct discovery sets and was combined using a risk‐score model. Different validation sets of GBMs and lower‐grade gliomas and different statistical methods were implemented for prognostic evaluation. An integrative analysis of multidimensional TCGA data was performed to molecularly characterize different risk tumors.Results: The six‐CpG risk‐score signature robustly predicted overall survival (OS) in all discovery and validation cohorts and in a treatment‐independent manner. It also predicted progression‐free survival (PFS) in available patients. The multimarker epigenetic signature was demonstrated as an independent prognosticator and had better performance than known molecular indicators such as glioma‐CpG island methylator phenotype (G‐CIMP) and proneural subtype. The defined risk subgroups were molecularly distinct; high‐risk tumors were biologically more aggressive with concordant activation of proangiogenic signaling at multimolecular levels. Accordingly, we observed better OS benefits of bevacizumab‐contained therapy to high‐risk patients in independent sets, supporting its implication in guiding usage of antiangiogenic therapy. Finally, the six‐CpG signature refined the risk classification based on G‐CIMP and MGMT methylation status.Conclusions: The novel six‐CpG signature is a robust and independent prognostic indicator for GBMs and is of promising value to improve personalized management.

22 March 2025 in Biomaterials
Verified
Journal Article
Closed access
JLJiajia Lu
Jiajia Lu
JCJiao Cai
Jiao Cai
ZZZhibin Zhou
Zhibin Zhou
JMJun Ma
Jun Ma
THTianyu Han
Tianyu Han
LZLei Zhu
Lei Zhu

8 July 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
JLJiajia Lu
Jiajia Lu
XWXinyu Wang
Xinyu Wang
NLNan Lu
Nan Lu
ACAimin Chen
Aimin Chen
LXLianbo Xiao
Lianbo Xiao
This study aims to elucidate the regulatory mechanisms of osteogenic differentiation in human periosteal stem cells (hPSCs) under hypoxia, focusing on the HIF‐1α/miR‐129‐5p/BMP2 axis. RNA‐seq identified miRNAs involved in hypoxia‐induced differentiation, and key molecules were validated at molecular and cellular levels. Hypoxia significantly enhanced osteogenic differentiation, as demonstrated by increased mineralization and upregulated osteogenic markers (BMP2, RUNX2, and Osterix). miR‐129‐5p was downregulated under hypoxia, and its overexpression suppressed BMP2 expression, indirectly affecting HIF‐1α levels and weakening osteogenic differentiation. HIF‐1α was identified as an upstream regulator of these miRNA changes. These findings provide new insights into the role of hypoxia in bone regeneration and offer potential strategies for bone repair and stem cell therapy.

16 December 2025 in Advanced Functional Materials
Verified
Journal Article
Closed access
JLJiajia Lu
Jiajia Lu
SWSheng Wang
Sheng Wang
RWRui Wu
Rui Wu
XSXiaojian Shi
Xiaojian Shi
DXDemeng Xia
Demeng Xia
LZLei Zhu
Lei Zhu

27 March 2024 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
XSXiaojian Shi
Xiaojian Shi
QFQiang Fu
Qiang Fu
JMJianyu Mao
Jianyu Mao
JYJiajie Yang
Jiajie Yang
YCYe Chen
Ye Chen
NLNan Lu
Nan Lu
Integrin‐based focal adhesion is one of the major mechanosensory in osteocytes. The aim of this study was to mine the hub genes associated with focal adhesion and investigate their roles in osteoporosis based on the data of single‐cell RNA sequencing and RNA‐sequencing. Two hub genes (FAM129A and RNF24) with the same expression trend and AUC values greater than 0.7 in both GSE56815 and GSE56116 cohorts were uncovered. The nomogram was created to predict the risk of OP based on two hub genes. Subsequently, the competing endogenous RNA network was established based on two hub genes, 14 microRNAs and five long noncoding RNAs. Meanwhile, transcription factors‐hub gene network was established based on two hub genes and 14 TFs. Finally, 73 drugs were predicted, of which there were 13 drugs targeting FAM129A and 66 drugs targeting RNF24. In both mouse and human blood samples, FAM129A expression was decreased in granulocytes and RNF24 expression was increased in monocytes. In the mouse experiment, FAM129A and anti‐RNF24 were found to partially alleviate the progression of osteoporosis. In conclusion, two hub genes related to focal adhesion were identified by combined scRNA‐seq and RNA‐seq analyses, which might supply a new insight for the treatment and evaluation of OP.